Specialized Pro-resolving Mediators in Cardiovascular Diseases

Overview

Journal Mol Aspects Med

Specialties Biochemistry
Molecular Biology

Date 2017 Mar 5

PMID 28257820

Citations 39

Authors

Gabrielle Fredman

Matthew Spite

Affiliations

Soon will be listed here.

Abstract

The resolution of inflammation is a highly regulated process enacted by endogenous mediators including specialized pro-resolving lipid mediators (SPMs): the lipoxins, resolvins, protectins and maresins. SPMs activate specific cellular receptors to temper the production of pro-inflammatory mediators, diminish the recruitment of neutrophils, and promote the clearance of dead cells by macrophages. These mediators also enhance host-defense and couple resolution of inflammation to subsequent phases of tissue repair. Given that unresolved inflammation plays a causal role in the development of cardiovascular diseases, an understanding of these endogenous pro-resolving processes is critical for determining why cardiovascular inflammation does not resolve. Here, we discuss the receptor-dependent actions of resolvins and related pro-resolving mediators and highlight their emerging roles in the cardiovascular system. We propose that stimulating resolution could be a novel approach for treating chronic cardiovascular inflammation without promoting immunosuppression.

Citing Articles

Early-age efferocytosis directs macrophage arachidonic acid metabolism for tissue regeneration.

Lantz C, Becker A, DeBerge M, Filipp M, Glinton K, Ananthakrishnan A Immunity. 2025; 58(2):344-361.e7.

PMID: 39938482 PMC: 11839170. DOI: 10.1016/j.immuni.2024.11.018.

The Involvement of Resolvins in Pathological Mechanisms of Periodontal Disease Associated with Type 2 Diabetes: A Narrative Review.

Ghemis L, Goriuc A, Jipu R, Foia L, Luchian I Int J Mol Sci. 2024; 25(23.

PMID: 39684494 PMC: 11641189. DOI: 10.3390/ijms252312784.

Dynamic changes in proresolving lipid mediators and their receptors following acute vascular injury in male rats.

Kagaya H, Kim A, Chen M, Lin P, Yin X, Spite M Physiol Rep. 2024; 12(15):e16178.

PMID: 39128880 PMC: 11317191. DOI: 10.14814/phy2.16178.

The analgesic effects of Yu-Xue-Bi tablet (YXB) on mice with inflammatory pain by regulating LXA4-FPR2-TRPA1 pathway.

Liu Y, Zhang G, Zhu C, Yao X, Wang W, Shen L Chin Med. 2024; 19(1):104.

PMID: 39107849 PMC: 11302111. DOI: 10.1186/s13020-024-00975-1.

Coronary microvascular dysfunction as a chronic inflammatory state: Is there a role for omega-3 fatty acid treatment?.

Keeley E, Handberg E, Wei J, Merz C, Pepine C Am Heart J Plus. 2024; 13:100098.

PMID: 38560085 PMC: 10978178. DOI: 10.1016/j.ahjo.2022.100098.

References

Ross R, GLOMSET J, Harker L . Response to injury and atherogenesis. Am J Pathol. 1977; 86(3):675-84. PMC: 2032127. View

Schrijvers D, De Meyer G, Kockx M, Herman A, Martinet W . Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(6):1256-61. DOI: 10.1161/01.ATV.0000166517.18801.a7. View

Lance K, Chatterjee A, Wu B, Mottola G, Nuhn H, Lee P . Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. J Biomed Mater Res A. 2016; 105(1):31-41. PMC: 5124518. DOI: 10.1002/jbm.a.35861. View

Chiang N, Fredman G, Backhed F, Oh S, Vickery T, Schmidt B . Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012; 484(7395):524-8. PMC: 3340015. DOI: 10.1038/nature11042. View

Chiang N, Hurwitz S, Ridker P, Serhan C . Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol. 2005; 26(2):e14-7. DOI: 10.1161/01.ATV.0000196729.98651.bf. View

Fredman G, Van Dyke T, Serhan C . Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010; 30(10):2005-13. PMC: 2982748. DOI: 10.1161/ATVBAHA.110.209908. View

Tabas I . Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2009; 10(1):36-46. PMC: 2854623. DOI: 10.1038/nri2675. View

Akagi D, Chen M, Toy R, Chatterjee A, Conte M . Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015; 29(6):2504-13. PMC: 4447226. DOI: 10.1096/fj.14-265363. View

Cai B, Thorp E, Doran A, Subramanian M, Sansbury B, Lin C . MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A. 2016; 113(23):6526-31. PMC: 4988577. DOI: 10.1073/pnas.1524292113. View

10.

Li S, Sun Y, Liang C, Thorp E, Han S, Jehle A . Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res. 2009; 105(11):1072-82. PMC: 2818555. DOI: 10.1161/CIRCRESAHA.109.199570. View

11.

Spite M, Claria J, Serhan C . Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2013; 19(1):21-36. PMC: 3947989. DOI: 10.1016/j.cmet.2013.10.006. View

12.

Cooray S, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark A . Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A. 2013; 110(45):18232-7. PMC: 3831442. DOI: 10.1073/pnas.1308253110. View

13.

Doring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S . Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. 2012; 110(8):1052-6. DOI: 10.1161/CIRCRESAHA.112.265868. View

14.

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

15.

Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald J . D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013; 27(6):2220-32. PMC: 3659350. DOI: 10.1096/fj.12-225615. View

16.

Cheuk B, Cheng S . Annexin A1 expression in atherosclerotic carotid plaques and its relationship with plaque characteristics. Eur J Vasc Endovasc Surg. 2011; 41(3):364-71. DOI: 10.1016/j.ejvs.2010.11.021. View

17.

Kusters D, Chatrou M, Willems B, De Saint-Hubert M, Bauwens M, van der Vorst E . Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet. PLoS One. 2015; 10(6):e0130484. PMC: 4475013. DOI: 10.1371/journal.pone.0130484. View

18.

Schwab J, Chiang N, Arita M, Serhan C . Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007; 447(7146):869-74. PMC: 2757086. DOI: 10.1038/nature05877. View

19.

Howangyin K, Zlatanova I, Pinto C, Ngkelo A, Cochain C, Rouanet M . Myeloid-Epithelial-Reproductive Receptor Tyrosine Kinase and Milk Fat Globule Epidermal Growth Factor 8 Coordinately Improve Remodeling After Myocardial Infarction via Local Delivery of Vascular Endothelial Growth Factor. Circulation. 2016; 133(9):826-39. PMC: 4767109. DOI: 10.1161/CIRCULATIONAHA.115.020857. View

20.

Zhang M, Sansbury B, Hellmann J, Baker J, Guo L, Parmer C . Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation. Circulation. 2016; 134(9):666-680. PMC: 5214591. DOI: 10.1161/CIRCULATIONAHA.116.021894. View